, The International Society for the Study of Vascular Anomalies, 2015.
Les malformations vasculaires superficielles: classification et histopathologie, Ann Pathol, vol.19, pp.253-264, 1999. ,
Vascular anomalies classification: recommendations from the International Society for the Study of Vascular Anomalies, Pediatrics, vol.136, pp.203-214, 2015. ,
Vascular tumors and vascular malformations (new issues), Adv Dermatol, vol.13, pp.375-423, 1997. ,
Update on vascular tumors of infancy, Curr Opin Pediatr, vol.22, pp.432-437, 2010. ,
Other vascular tumors, Semin Pediatr Surg, vol.23, pp.173-177, 2014. ,
Efficacy of pulsed dye laser treatment of port wine stain malformations of the lower limb, Br J Dermatol, vol.149, pp.770-775, 2003. ,
Treatment of childhood lymphangiomas with interferon-alpha, J Pediatr Hematol Oncol, vol.19, pp.232-236, 1997. ,
Cyclophosphamide in nonresectable cystic hygroma, Lancet, vol.335, pp.1474-1475, 1990. ,
Propranolol as an alternative treatment option for pediatric lymphatic malformation, Tohoku J Exp Med, vol.229, pp.61-66, 2013. ,
Multimodality treatment of pediatric lymphatic malformations of the head and neck using surgery and sclerotherapy, Arch Otolaryngol Head Neck Surg, vol.136, pp.270-276, 2010. ,
Efficacy and safety of embolization in arteriovenous malformations of the extremities and head and neck: a retrospective study of 32 cases, Eur J Dermatol, vol.25, pp.52-56, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-02630885
Propranolol for severe hemangiomas of infancy, N Engl J Med, vol.358, pp.2649-2651, 2008. ,
Corticosteroid treatment of cutaneous hemangiomas: how effective? A report on 24 children, Clin Pediatr (Phila), vol.17, pp.629-638, 1978. ,
Kasabach-Merritt phenomenon: a retrospective study of treatment with vincristine, J Pediatr Hematol Oncol, vol.24, pp.459-462, 2002. ,
Treatment of massive or life-threatening hemangiomas with recombinant alpha(2a)-interferon, Otolaryngol Head Neck Surg, vol.17, pp.99-110, 1997. ,
Kasabach-Merritt syndrome-associated kaposiform hemangioendothelioma successfully treated with cyclophosphamide, vincristine, and actinomycin D, J Pediatr Hematol Oncol, vol.20, pp.567-569, 1998. ,
Current knowledge and management of vascular anomalies: I. Hemangiomas, Arch Facial Plast Surg, vol.13, pp.145-151, 2011. ,
Complex vascular anomalies, Pediatr Surg Int, vol.29, pp.1023-1038, 2013. ,
Treatment of childhood kaposiform hemangioendothelioma with sirolimus, Pediatr Blood Cancer, vol.55, pp.1396-1398, 2010. ,
Sirolimus for the treatment of complicated vascular anomalies in children, Pediatr Blood Cancer, vol.57, pp.1018-1024, 2011. ,
Rapamycin treatment for a child with germline PTEN mutation, Nat Clin Pract Oncol, vol.5, pp.357-361, 2008. ,
Rapamycin: something old, something new, sometimes borrowed and now renewed, Clin Pharmacol Ther, vol.82, pp.381-388, 2007. ,
AKT1 overexpression in endothelial cells leads to the development of cutaneous vascular malformations in vivo, Arch Dermatol, vol.143, pp.504-506, 2007. ,
Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization, J Antibiot (Tokyo), vol.28, pp.727-732, 1975. ,
Preclinical evaluation of a new potent immunosuppressive agent, rapamycin, Transplantation, vol.52, pp.185-191, 1991. ,
Efficacy of temsirolimus in metastatic chro-mTOR inhibitors and vascular anomalies mophobe renal cell carcinoma, BMC Urol, vol.13, p.26, 2013. ,
Efficacy of sirolimus compared with azathioprine for the reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group, Lancet, vol.356, pp.194-202, 2000. ,
Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study, Am J Transplant, vol.15, pp.119-128, 2015. ,
Estimating the contribution of everolimus to immunosuppressive efficacy when combined with tacrolimus in liver transplantation: a model-based approach, Clin Pharmacol Ther, vol.97, pp.411-418, 2015. ,
Everolimus exposure in cardiac transplant recipients is influenced by concomitant calcineurin inhibitor, Ther Drug Monit, vol.30, pp.113-116, 2008. ,
Clinical efficacy and management of temsirolimus in patients with relapsed or refractory mantle cell lymphoma, Clin Lymphoma Myeloma Leuk, vol.13, pp.351-359, 2013. ,
Targeted therapies for renal cell carcinoma in Chinese patients: focus on everolimus, Onco Targets Ther, vol.8, pp.313-321, 2015. ,
Everolimus plus exemestane in postmenopausal patients with HR (+) breast cancer: BOLERO-2 final progression-free survival analysis, Adv Ther, vol.30, pp.870-884, 2013. ,
Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors. A subgroup analysis of the phase III RADIANT-3 trial, Pancreas, vol.44, pp.181-189, 2015. ,
Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex, Biologics, vol.7, pp.211-221, 2013. ,
Deforolimus (AP23573) a novel mTOR inhibitor in clinical development, Expert Opin Investig Drugs, vol.17, pp.1947-1954, 2008. ,
Targeting the mTOR pathway using deforolimus in cancer therapy, Future Oncol, vol.5, pp.291-303, 2009. ,
Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer, Gynecol Oncol, vol.135, pp.184-189, 2014. ,
The spectrum of vascular anomalies in patients with PTEN mutations: implications for diagnosis and management, J Med Genet, vol.44, pp.594-602, 2007. ,
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor, Nat Med, vol.8, pp.128-135, 2002. ,
Marastoni S. MTOR pathway and mTOR inhibitors as agents for cancer therapy, Curr Cancer Drug Targets, vol.8, pp.647-665, 2008. ,
Expression of prox1, lymphatic endothelial nuclear transcription factor, in Kaposiform hemangioendothelioma and tufted angioma, Am J Surg Pathol, vol.34, pp.1563-1573, 2010. ,
Visualization of embryonic lymphangiogenesis advances the use of the zebrafish model for research in cancer and lymphatic pathologies, Dev Dyn, vol.239, pp.2128-2135, 2010. ,
Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis, Cancer Sci, vol.98, pp.726-733, 2007. ,
Indications, tolerance and complications of a sirolimus and calcineurin inhibitor immunosuppression regimen: intermediate experience in pediatric heart transplantation recipients, Pediatr Transplant, vol.14, pp.402-408, 2010. ,
Efficacy and safety of a mammalian target of rapamycin inhibitor in pediatric patients with tuberous sclerosis complex: a systematic review and meta-analysis, Exp Ther Med, vol.9, pp.626-630, 2015. ,
Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer, J Clin Oncol, vol.22, pp.2336-2347, 2004. ,
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies, Clin Cancer Res, vol.12, pp.5165-5173, 2006. ,
Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients with advanced soft tissue or bone sarcomas, J Clin Oncol (Meeting Abstracts), vol.24, p.9505, 2006. ,
Brief communication: sirolimusassociated pneumonitis: 24 cases in renal transplant recipients, Ann Intern Med, vol.144, pp.505-509, 2006. ,